{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:34:39Z","timestamp":1787924079332,"version":"build-2784847793"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapsed\/refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL\/T-LBL) has poor outcomes and limited salvage options. Objectives: To evaluate the efficacy and safety of daratumumab-based therapy in R\/R T-ALL\/T-LBL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review of observational reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixteen reports including 34 patients treated with daratumumab-based regimens were reviewed. Baseline characteristics, treatment patterns, response, MRD status, survival, allogeneic HSCT, and safety were descriptively synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Complete remission was reported in 30\/34 patients (88.2%), partial remission in 2\/34 (5.9%), and no response in 2\/34 (5.9%). Among complete responders with reported MRD status, 24\/29 (82.8%) achieved MRD negativity. Median PFS was 10 months (range, 0.4\u201345), and median OS was 10 months (range, 1.5\u201345), although many values reflected last follow-up. Eighteen patients (52.9%) proceeded to allogeneic HSCT; 13\/18 (72.2%) were alive at last follow-up. Infusion reactions occurred in 10 patients, mostly grade 1\u20132.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Daratumumab-based therapy may induce remission and facilitate HSCT bridging in selected patients, but findings remain hypothesis-generating because evidence is mainly from case reports and small series.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261484097","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:31:22Z","timestamp":1787686282000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CD38 in relapsed \/refractory T-cell acute lymphoblastic leukemia\/lymphoma: A systematic review of daratumumab-based therapy"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-5302","authenticated-orcid":false,"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"first","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujahid O.","family":"Abdelraof","sequence":"additional","affiliation":[{"name":"Gezira University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Gezira University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8455","authenticated-orcid":false,"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25990"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07499.x"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024493"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05775-z"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06474-z"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14310"},{"key":"e_1_3_7_8_2","first-page":"232","article-title":"Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression","volume":"42","author":"Feng L-S","year":"2025","unstructured":"Feng L-S, Li H-Y, Tang A, et al. Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression. Turk J Haematol 2025; 42: 232\u2013234. https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0019","journal-title":"Turk J Haematol"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-794214"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283740"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0222-5"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030512"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05892-9"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1901097"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16154"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9722787"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0548-z"},{"key":"e_1_3_7_22_2","unstructured":"Peng L Dai Y Ren J. COMBINATION OF VENETOCLAX AND DARATUMUMAB PLUS CAG REGIMEN IS AN EFFECTIVE TRANSPLANT BRIDGING REGIMEN IN ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSITIVE MINIMAL RESIDUAL DISEASE. https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160469\/li-jun.peng.combination.of.venetoclax.and.daratumumab.plus.cag.regimen.is.an.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Ddaratumumab (accessed 12 December 2025)."},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1228481"},{"key":"e_1_3_7_24_2","first-page":"528","article-title":"Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab","volume":"11","author":"Punatar S","year":"2021","unstructured":"Punatar S, Gokarn A, Nayak L, et al. Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab. American Journal of Blood Research 2021; 11: 528\u2013533.","journal-title":"American Journal of Blood Research"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28829"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29779"},{"key":"e_1_3_7_27_2","first-page":"829","article-title":"A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia\/lymphoma patient","volume":"104","author":"Yi\u011fit Kaya S","year":"2025","unstructured":"Yi\u011fit Kaya S, Vatani M, Akil R, et al. A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia\/lymphoma patient. Annals of Hematology 2025; 104: 829\u2013833. https:\/\/doi.org\/10.1007\/s00277-024-06118-8","journal-title":"Annals of Hematology"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25896"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026118"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2910"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30105-8"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015441"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021184"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000006"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01638-7"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279851"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.05.007"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261484097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261484097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261484097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:10:48Z","timestamp":1787922648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261484097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["10.1177\/20406207261484097"],"URL":"https:\/\/doi.org\/10.1177\/20406207261484097","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20406207261484097"}}